Evidence map›Paper›PMID 32508810›Full record

ArticleFrontiers in immunology2020

Fli1 Downregulation in Scleroderma Myeloid Cells Has Profibrotic and Proinflammatory Effects.

Andreea M Bujor, Fatima El Adili, Arshi Parvez, Grace Marden, Maria Trojanowska

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
1.3field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 27 citations in OpenAlex.

  1. Review
  2. Article
  3. Targeting endothelial ERG to mitigate vascular regression in retinopathies.Proceedings of the National Academy of Sciences of the United States of America · 2025
    Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Epigenetic Modifications in the Pathogenesis of Systemic Sclerosis.International journal of general medicine · 2022
    Review
  14. Article
  15. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Andreea M BujorDivision of Rheumatology, Department of Medicine, Arthritis and Autoimmune Diseases Research Center, Boston University School of Medicine, Boston, MA, United States.
Fatima El AdiliDivision of Rheumatology, Department of Medicine, Arthritis and Autoimmune Diseases Research Center, Boston University School of Medicine, Boston, MA, United States.
Arshi ParvezDivision of Rheumatology, Department of Medicine, Arthritis and Autoimmune Diseases Research Center, Boston University School of Medicine, Boston, MA, United States.
Grace MardenDivision of Rheumatology, Department of Medicine, Arthritis and Autoimmune Diseases Research Center, Boston University School of Medicine, Boston, MA, United States.
Maria TrojanowskaDivision of Rheumatology, Department of Medicine, Arthritis and Autoimmune Diseases Research Center, Boston University School of Medicine, Boston, MA, United States.
Boston University · US

Funding

Multidisciplinary Training in Cardiovascular ResearchT32HL007224 · NHLBI · BOSTON UNIVERSITY MEDICAL CAMPUS · PI HAMBURG, NAOMI MIRIAM, WAINFORD, RICHARD DAVID · 1985 to 2020
$12.3M
The molecular mechanisms of fibrosisR01AR042334 · NIAMS · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI TROJANOWSKA, MARIA · 1994 to 2018
$5.2M
NHLBI NIH HHS T32 HL007224NIAMS NIH HHS R01 AR042334
6 · The paper itself

Abstract

Scleroderma (SSc) is an autoimmune connective tissue disease characterized by immune dysregulation, vasculopathy, and fibrosis. We have previously demonstrated that low Fli1 expression in SSc fibroblasts and endothelial cells plays an important role in SSc pathogenesis. Cells of myeloid and lymphoid origin also express Fli1 and are dysregulated in patients with SSc, playing key roles in disease pathogenesis. However, the role for immune Fli1 in SSc is not yet clear. Our aim was to elucidate whether Fli1 contributes to the immune dysregulation seen in SSc. Comparison of the expression of Fli1 in monocytes, B- and T-cell fractions of PBMCs isolated from SSc patients and healthy controls (HC), showed an increase in Fli1 levels in monocytes. We used siRNA transfected human myeloid cells and mouse peritoneal macrophages obtained from

Indexed as

AnimalsAutoimmune DiseasesCells, CulturedCoculture TechniquesDisease Models, AnimalDown-RegulationFibroblastsFibrosisGene ExpressionHealthy VolunteersHumansMacrophages, PeritonealMiceMice, Inbred C57BLMice, KnockoutMice, TransgenicFLI1 protein, humanProto-Oncogene Protein c-fli-1RNA, Small InterferingTransforming Growth Factor betafibroblastsfibrosisFli1macrophagesmonocytesscleroderma

Identifiers

PMID32508810
PMCPMC7248379
OpenAlexW3028355331

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.